Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 11/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL544947 | 0.90 | LMNA (0.36) | RORCLMNACYP2C9TSHRBLM | |
| SCHEMBL544862 | 0.86 | LMNA (0.36) | RORCLMNACYP2C9TSHRBLM | |
| SCHEMBL545374 | 0.85 | RORC (0.42) | KDM1ARCOR1RORCLMNACYP2C9 | |
| SCHEMBL544943 | 0.85 | MEN1 (0.41) | KDM1ARORCLMNACYP2C9TSHR | |
| SCHEMBL545026 | 0.84 | KDM1A (0.43) | KDM1ARCOR1RORCLMNATSHR | |
| SCHEMBL545048 | 0.77 | NR3C2 (0.52) | LMNACYP2C9TSHRMAPT | |
| SCHEMBL544728 | 0.76 | SMN1; SMN2 (0.40) | RORCLMNACYP2C9MAPT | |
| SCHEMBL10071238 | 0.72 | KDM1A (0.47) | KDM1ARCOR1 | |
| SCHEMBL12860010 | 0.70 | GAA (0.37) | KDM1ARCOR1LMNATSHR | |
| SCHEMBL544636 | 0.70 | GAA (0.42) | KDM1ARCOR1RORCLMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110699-B2 | Cobalt-catalyzed asymmetric cyclopropanation of alkenes with α-nitrodiazoacetates | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100081838-A1 | Cobalt-Catalyzed Asymmetric Cyclopropanation of Alkenes with alpha-Nitrodiazoacetates | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081838-A1 | Cobalt-Catalyzed Asymmetric Cyclopropanation of Alkenes with alpha-Nitrodiazoacetates | PPOX, IDH3A, HMOX2 | KDM1A 1406/4885RCOR1 1859/4885RORC 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.